Key Points
- Director James Wilson sold 10,000 shares for $726,700 at an average price of $72.67, reducing his stake by 0.95%; he still owned 1,044,543 shares after the sale.
- Corcept reported quarterly EPS of $1.01, beating the $0.84 consensus estimate, while revenue rose 64% year over year to $340.47 million.
- Analysts’ consensus rating was “Moderate Buy,” with an average price target of $139.50; five analysts rated the stock Buy, two Hold, and one Sell.
Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) Director James Wilson sold 10,000 shares of the stock in a transaction that occurred on Friday, November 13th. The stock was sold at an average price of $72.67, for a total transaction of $726,700.00. Following the completion of the sale, the director owned 1,044,543 shares of the company's stock, valued at approximately $75,906,939.81. The trade was a 0.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Corcept Therapeutics Stock Up 1.2%
Shares of NASDAQ:CORT opened at $70.07 on Wednesday. The firm has a fifty day moving average of $101.97 and a two-hundred day moving average of $76.68. The firm has a market capitalization of $7.67 billion, a P/E ratio of 55.17 and a beta of 0.54. Corcept Therapeutics Incorporated has a 12-month low of $28.66 and a 12-month high of $126.38.
Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The biotechnology company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.84 by $0.17. Corcept Therapeutics had a net margin of 16.53% and a return on equity of 22.56%. The business had revenue of $340.47 million for the quarter, compared to analysts' expectations of $339.12 million. During the same period in the previous year, the company posted $0.16 EPS. Corcept Therapeutics's revenue was up 64.0% on a year-over-year basis. Equities research analysts expect that Corcept Therapeutics Incorporated will post 1.97 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of brokerages have commented on CORT. Truist Financial began coverage on Corcept Therapeutics in a research note on Tuesday, August 18th. They issued a "buy" rating and a $164.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $165.00 price target on shares of Corcept Therapeutics in a research note on Friday, September 18th. Zacks Research downgraded Corcept Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, October 27th. Wall Street Zen upgraded Corcept Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 1st. Finally, Canaccord Genuity Group boosted their price target on Corcept Therapeutics from $135.00 to $150.00 and gave the company a "buy" rating in a research note on Wednesday, July 29th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $139.50.
Get Our Latest Stock Analysis on CORT
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Alberta Investment Management Corp acquired a new stake in shares of Corcept Therapeutics in the 2nd quarter valued at $9,843,000. BlackRock Inc. bought a new stake in Corcept Therapeutics in the second quarter worth $1,080,964,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Corcept Therapeutics in the second quarter worth $2,311,000. NewEdge Wealth LLC bought a new stake in Corcept Therapeutics in the second quarter worth $3,034,000. Finally, Evanson Financial LLC acquired a new position in Corcept Therapeutics during the second quarter worth $1,085,000. Institutional investors and hedge funds own 93.61% of the company's stock.
Corcept Therapeutics Company Profile
(
Get Free Report)
Corcept Therapeutics is a biopharmaceutical company focused on developing medicines that modulate the effects of cortisol, a hormone involved in the body's response to stress and in several disease processes. Founded in 1998, the company conducts research and develops treatments for conditions in which cortisol may play a role. Its marketed product, Korlym (mifepristone), is approved in the United States to control high blood sugar in adults with endogenous Cushing's syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or have not benefited from it.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].